| Code | CSB-RA017712MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to olaratumab, targeting platelet-derived growth factor receptor alpha (PDGFRA). PDGFRA is a receptor tyrosine kinase that plays a critical role in cellular proliferation, differentiation, and survival by binding platelet-derived growth factors. Upon ligand binding, PDGFRA undergoes dimerization and autophosphorylation, initiating downstream signaling cascades including the PI3K/AKT and MAPK pathways. Aberrant PDGFRA signaling is implicated in various malignancies, including soft tissue sarcomas, glioblastomas, and gastrointestinal stromal tumors, where receptor overexpression or activating mutations contribute to tumor growth and progression.
Olaratumab was developed as a fully humanized IgG1 monoclonal antibody that blocks PDGFRA ligand binding, thereby inhibiting receptor activation and downstream oncogenic signaling. This biosimilar antibody provides researchers with a valuable tool for investigating PDGFRA-mediated pathways in cancer biology, studying receptor-ligand interactions, and exploring therapeutic mechanisms of PDGFRA blockade. It supports studies examining tumor microenvironment dynamics, angiogenesis, and stromal cell interactions in PDGFRA-driven diseases.
There are currently no reviews for this product.